In contrast, the second-generation XPO1 inhibitor, eltanexor [63], has demonstrated the ability to cause an irreversible downregulation of HOX genes, inducing the terminal differentiation of AML cells and prolonging the survival of leukemic mice. This evidence concerns the gene XPO1 and acute myeloid leukemia.